Cargando…

PD-L1 testing and immunotherapy selection – early laboratory experience and its potential role in head and neck cancer management

Anti-programmed cell death protein-1 (PD-1) therapy has been relatively recently approved in a defined context by NICE in adults in the management of recurrent and metastatic head and neck squamous cell carcinomas (HNSCC). In this context, companion diagnostic programmed cell death ligand-1 (PD-L1)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bancu, Andrei, Cowan, Richard, Chaturvedi, Anshuman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	UMF “Gr. T. Popa” Iasi Publishing House 2021
Materias:	Original Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565705/ https://www.ncbi.nlm.nih.gov/pubmed/34754934 http://dx.doi.org/10.22551/2021.30.0801.10179

Ejemplares similares

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020)

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023)

PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
por: Hirata-Nozaki, Yui, et al.
Publicado: (2019)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

PD-L1 expressing circulating tumour cells in head and neck cancers
por: Kulasinghe, Arutha, et al.
Publicado: (2017)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Prevention and Early Detection of Head and Neck Squamous Cell Cancers
por: Nagao, Toru, et al.
Publicado: (2011)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
por: Rasmussen, Jacob H., et al.
Publicado: (2019)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

Vaccine-Based Immunotherapy for Head and Neck Cancers
por: Beyaert, Simon, et al.
Publicado: (2021)

Editorial: Immunology and Immunotherapy of Head and Neck Cancer
por: Gavrielatou, Niki, et al.
Publicado: (2021)

Combining Radiotherapy and Immunotherapy in Head and Neck Cancer
por: Runnels, Juliana, et al.
Publicado: (2023)

Gargle test for successful extubation in critically ill patients underwent head and neck surgeries: A new test
por: Beigmohammadi, Mohammad Taghi, et al.
Publicado: (2022)

PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
por: Crosta, Simona, et al.
Publicado: (2021)

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
por: Ran, Xiongwen, et al.
Publicado: (2017)

IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer
por: Zhao, Yi, et al.
Publicado: (2021)

PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
por: Malinowska, Katarzyna, et al.
Publicado: (2023)

Evaluation of Reirradiation in Locally Advanced Head and Neck Cancers: Toxicity and Early Clinical Outcomes
por: Bahl, Amit, et al.
Publicado: (2018)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1
por: Kossai, M., et al.
Publicado: (2021)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?
por: Patil, V., et al.
Publicado: (2013)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
por: Müller, Tim, et al.
Publicado: (2017)

PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells
por: Eichberger, Jonas, et al.
Publicado: (2020)

HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings
por: Boschert, Verena, et al.
Publicado: (2020)

Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck
por: Zahnreich, Sebastian, et al.
Publicado: (2021)

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

PD-L1 and HIF-2α Upregulation in Head and Neck Paragangliomas after Embolization
por: Fischer, Alessa, et al.
Publicado: (2023)

PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection
por: Lyu, Xintong, et al.
Publicado: (2019)

The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
por: Wang, Bi‐Cheng, et al.
Publicado: (2019)

Immunotherapy of Head and Neck Cancer: Current and Future Considerations
por: Rapidis, Alexander D., et al.
Publicado: (2009)

Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy
por: Abu Eid, Rasha
Publicado: (2019)

Immunotherapy in head and neck cancer: aiming at EXTREME precision
por: Szturz, Petr, et al.
Publicado: (2017)

Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
por: Economopoulou, Panagiota, et al.
Publicado: (2020)

Epigenetic modulation of immunotherapy and implications in head and neck cancer
por: Zhou, Liye, et al.
Publicado: (2021)

Immunotherapy Approaches in HPV-Associated Head and Neck Cancer
por: Julian, Ricklie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_egugroqur4v2gbckea88n2jqbj